I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Andrea Lynn Richardson, M.D., Ph.D.
Associate Professor of Pathology
Sibley Memorial Hospital
5255 Loughboro Rd NW
Washington, DC 20016 map
Dr. Andrea Richardson received her M.D. and Ph.D. degrees from University of Texas Southwestern Medical and Graduate Schools in Dallas, TX in 1992. She completed her residency training in Anatomic Pathology with subspecialty training in breast pathology and cytopathology at Brigham and Women's Hospital Harvard Medical School in Boston, MA.
From 1997 to 1993, she was on anatomic pathology staff in the Department of Pathology and Laboratory Medicine at Harvard Vanguard Medical Associates in Boston.
In 2000, she returned to the Department of Pathology, Brigham and Women’s Hospital and Department of Cancer Biology, Dana Farber Cancer Institute. There, she maintained an active clinical practice on the BWH breast pathology consultation service and a translational research laboratory and rose to the rank of Associate Professor of Pathology at Harvard Medical School.
Her research interests have focused on molecular pathology of breast cancer and development of predictive biomarkers of treatment response.
In 2015, she joined the faculty of Johns Hopkins School of Medicine as Director of Pathology, Community Practice Division and Director of Breast Pathology, Community Practice Division.
Her clinical practice is based at Sibley Memorial Hospital, Washington DC. She will also continue her translational breast cancer research with collaborators at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
- Associate Professor of Pathology
- Associate Professor of Oncology
- MD, University of Texas Southwestern Medical Center at Dallas - REGISTRAR (1992)
- Brigham and Womens Hospital / Anatomic and Clinical Pathology (1998)
- American Board of Pathology / Anatomic Pathology (1997)
- American Board of Pathology / Cytopathology (1998)
Research & Publications
Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, Harris L, Ramaswamy S, Tanenbaum DM, Meyerson M, Iglehart JD, Richardson A. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res. 2004;64(1):64-71.
Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat. 2005;91(2):179-86.
Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006;9(2):121-32.
Lu X, Lu, X, Wang ZC, Iglehart JD, Zhang X, Richardson AL. Predicting Features of Breast Cancer with Gene Expression Patterns. Breast Cancer Res Treat 2008 Mar;108(2):191-201.
Silver DP*, Richardson AL*, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong C-O, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010 Mar 1;28(7):1145-53. Epub 2010 Jan 25.
Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, Desmedt C, Sotiriou C, Szallasi Z, Iglehart JD, Richardson AL*, Wang ZC*. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med. 2010 Feb;16(2):214-8. Epub 2010 Jan 24.
Tung N, Miron A, Schnitt SJ, Gautam S, Fetten K, Kaplan J, Yassin Y, Buraimoh A, Kim J-Y, Szasz AM, Tian R, Wang ZC, Collins LC, Brock JE, Krag K, Legare RD, Sgroi D, Ryan PD, Silver DP, Garber JE, Richardson AL. Prevalence and Predictors of Loss of wild type BRCA1 in Estrogen Receptor Positive and Negative BRCA1-associated Breast Cancers. Breast Cancer Res. 2010 12:R95 (16 November 2010)
Li Y, Zhang Q, Tian R, Wang Q, Zhao JJ, Iglehart JD, Wang ZC, Richardson AL. Lysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cells. Cancer Res. 2011;71 7481-7489
Birkbak NJ, Wang, ZC, Kim J-Y, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA damaging agents. Cancer Discovery, April 2012; 2(4): 366-375. doi:10.1158/2159-8290
Telli ML, Timms K, Reid J, Hennessy B, Mills G, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan P, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones J, Lanchbury JS, Hartman A-R, Garber JE, Ford JM, Silver DP, Richardson AL. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple negative breast cancer. Clin. Cancer Res. 2016 (in press).